Datasets:
instruction stringlengths 20 179 | output stringlengths 50 3k |
|---|---|
Give me an overview of the drug Lepirudin. | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the a... |
What are the clinical indications for Lepirudin? | Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with hepa... |
When should a clinician prescribe Lepirudin? | Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with hepa... |
Explain the mechanism of action of Lepirudin. | Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers ... |
How does Lepirudin work at a molecular level? | Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers ... |
Describe the pharmacodynamics of Lepirudin. | Lepirudin is a recombinant hirudin that acts as a highly specific thrombin inhibitor. Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization Ξ±-thrombin (89/588) standard. The activity of lepirudin is 16,000 ATU/mg.... |
What is the absorption profile of Lepirudin? | Lepirudin administered as a single intravenous bolus injection of 0.4 mg/kg in 9 healthy volunteers (male and female) resulted in a C<sub>max</sub> of 2924 ng/mL, a t<sub>max</sub> of 0.17 h and an AUC<sub>0-β</sub> of 2500 ngβ’h/mL.[L41539] When 0.1, 0.15 and 0.2 mg/kg of lepirudin was administered as a single intraven... |
What is the half-life of Lepirudin? | Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination kinetic; plasma concentration increases proportionally as the lepirudin intravenous dose is increased. Elimination half-life values o... |
What is the protein binding percentage of Lepirudin? | In human plasma, the protein binding of lepirudin was approximately 3%.[L41539] |
What are the toxic effects or overdose risks of Lepirudin? | The acute toxicity of intravenous lepirudin was evaluated in mice (0.1-1000 mg/kg), rats (1-1000 mg/kg), and monkeys (1-100 mg/kg), and toxicity was not detected at the doses investigated.[L41539] The acute toxicity of lepirudin administered subcutaneously was also evaluated in mice (1-1250 mg/kg) and rats (1-500 mg/kg... |
Give me an overview of the drug Cetuximab. | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour ... |
What are the clinical indications for Cetuximab? | Cetuximab is indicated for: - The treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. - The treatment of recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with [... |
When should a clinician prescribe Cetuximab? | Cetuximab is indicated for: - The treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. - The treatment of recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with [... |
Explain the mechanism of action of Cetuximab. | The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and recta... |
How does Cetuximab work at a molecular level? | The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and recta... |
Describe the pharmacodynamics of Cetuximab. | Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-Ξ±), which are natural ligands of EGFR.[L31418] Cetux... |
What is the absorption profile of Cetuximab? | After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the steady-state levels of cetuximab was reached by the third weekly infusion with mean peak and trough concentrations across studies ranging from 168 Β΅g/mL to 235 Β΅g/mL and 41 Β΅g/mL to 85 Β΅g/mL, respectively.[L3... |
What is the half-life of Cetuximab? | After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the mean half-life for cetuximab was approximately 112 hours, with a range of 63 to 230 hours.[L30448] |
What are the toxic effects or overdose risks of Cetuximab? | The intravenous LD<sub>50</sub> is > 300 mg/kg in mice and > 200 mg/kg in rats.[L31408] There is limited information on the overdose from cetuximab. In clinical trials, cetuximab was associated with serious and fatal infusion reactions, cardiopulmonary arrest or sudden death, and serious dermatologic toxicities. Pulmon... |
What is Dornase alfa? | Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to... |
Give me an overview of the drug Dornase alfa. | Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to... |
What are the clinical indications for Dornase alfa? | Used as adjunct therapy in the treatment of cystic fibrosis. |
When should a clinician prescribe Dornase alfa? | Used as adjunct therapy in the treatment of cystic fibrosis. |
Explain the mechanism of action of Dornase alfa. | Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5Β΄-phosphodinucleotide and 5Β΄-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and... |
How does Dornase alfa work at a molecular level? | Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5Β΄-phosphodinucleotide and 5Β΄-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and... |
Describe the pharmacodynamics of Dornase alfa. | Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of ... |
What is the absorption profile of Dornase alfa? | Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no m... |
What are the toxic effects or overdose risks of Dornase alfa? | Adverse reactions occur at a frequency of < 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis.... |
What is Denileukin diftitox? | Denileukin diftitox is an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met<sub>1</sub>-Thr<sub>387</sub>)-His and the sequence for human interleukin-2 (IL-2; Ala<sub>1</sub>-Thr<sub>133</sub>).[L51254] It is des... |
Give me an overview of the drug Denileukin diftitox. | Denileukin diftitox is an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met<sub>1</sub>-Thr<sub>387</sub>)-His and the sequence for human interleukin-2 (IL-2; Ala<sub>1</sub>-Thr<sub>133</sub>).[L51254] It is des... |
What are the clinical indications for Denileukin diftitox? | Denileukin diftitox was previously indicated for the treatment of adult patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.[L26381] It is also indicated for the treatment of adult patients with relapsed or refractory Stage I-III C... |
When should a clinician prescribe Denileukin diftitox? | Denileukin diftitox was previously indicated for the treatment of adult patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.[L26381] It is also indicated for the treatment of adult patients with relapsed or refractory Stage I-III C... |
Explain the mechanism of action of Denileukin diftitox. | Denileukin diftitox is a fusion protein composed of truncated diphtheria toxin (DT), which is a cytocidal moiety, and the full-length sequence of interleukin-2 (IL-2), which acts as a ligand for the IL-2 receptor.[A264344] Denileukin diftitox is reported to bind to a high- or intermediate-affinity receptor.[A264344] On... |
How does Denileukin diftitox work at a molecular level? | Denileukin diftitox is a fusion protein composed of truncated diphtheria toxin (DT), which is a cytocidal moiety, and the full-length sequence of interleukin-2 (IL-2), which acts as a ligand for the IL-2 receptor.[A264344] Denileukin diftitox is reported to bind to a high- or intermediate-affinity receptor.[A264344] On... |
Describe the pharmacodynamics of Denileukin diftitox. | Denileukin diftitox is an anticancer drug with cytocidal actions on cancer cells.[L51254] Denileukin diftitox demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (T<sub>regs</sub>) and antitumor activity through direct cytocidal action on IL-2R-expressing tumours.[L51254] |
What is the absorption profile of Denileukin diftitox? | Following a single dose of denileukin diftitox 9 mcg/kg via one-hour infusion in patients with CTCL, the geometric mean (coefficient of variation [CV]%) maximum serum concentration (C<sub>max</sub>) was 94.4 ng/mL (77%) and area under the concentration over time curve (AUC<sub>0-inf</sub>) was 20700 ng x min/L (60%) on... |
What is the half-life of Denileukin diftitox? | The arithmetic mean (CV%) denileukin diftitox terminal half-life is 112 minutes (31%) on the first day of the first cycle.[L51254] |
What are the toxic effects or overdose risks of Denileukin diftitox? | There is limited information regarding the acute toxicity (LD<sub>50</sub>) and overdose of denileukin diftitox. |
Give me an overview of the drug Etanercept. | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... |
What are the clinical indications for Etanercept? | Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[L14862,L45523] It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arth... |
When should a clinician prescribe Etanercept? | Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[L14862,L45523] It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arth... |
Explain the mechanism of action of Etanercept. | There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecul... |
How does Etanercept work at a molecular level? | There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecul... |
What is the absorption profile of Etanercept? | Population pharmacokinetic modeling in adults with RA, AS, or who were healthy showed a subcutaneous bioavailability of 56.9% with a Ka of 0.0223/h.[A215352] Another model in pediatric JIA patients showed an increased Ka of 0.05/h with a high mean interindividual variability of 215%.[A215357] Cmax after a single 25 mg ... |
What is the half-life of Etanercept? | Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pediatric JIA patients.[A215657,A215357] |
What happens when Etanercept is combined with Belimumab? | The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab. |
What happens when Etanercept is combined with Cyclophosphamide? | The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide. |
What happens when Etanercept is combined with Denosumab? | The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept. |
What is Bivalirudin? | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... |
Give me an overview of the drug Bivalirudin. | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... |
What are the clinical indications for Bivalirudin? | For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is plan... |
When should a clinician prescribe Bivalirudin? | For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is plan... |
Explain the mechanism of action of Bivalirudin. | Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalent... |
How does Bivalirudin work at a molecular level? | Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalent... |
Describe the pharmacodynamics of Bivalirudin. | Bivalirudin mediates an inhibitory action on thrombin by directly and specifically binding to both the catalytic site and anion-binding exosite of circulating and clot-bound thrombin. The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site... |
What is the absorption profile of Bivalirudin? | Following intravenous administration, bivalirudin exhibits linear pharmacokinetics. The mean steady state concentration is 12.3 +/- 1.7mcg/mL after administration of an intravenous bolus of 1mg/kg followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours. |
What is the half-life of Bivalirudin? | * Normal renal function: 25 min (in normal conditions) * Creatinine clearance 10-29mL/min: 57min * Dialysis-dependant patients: 3.5h |
What is the protein binding percentage of Bivalirudin? | Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins. |
How is Bivalirudin eliminated from the body? | Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage. |
What are the toxic effects or overdose risks of Bivalirudin? | Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h. |
Give me an overview of the drug Leuprolide. | Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours.[A203222] As a Gn... |
What are the clinical indications for Leuprolide? | Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790] It is also used for the treatment of pediatric patients with central precocious puberty (CPP).[L13784, L13787] In combination with oral [norethisterone] (also known as ... |
When should a clinician prescribe Leuprolide? | Leuprolide is indicated for the treatment of advanced prostate cancer [L13781, L34415] and as palliative treatment of advanced prostate cancer.[L13790] It is also used for the treatment of pediatric patients with central precocious puberty (CPP).[L13784, L13787] In combination with oral [norethisterone] (also known as ... |
Explain the mechanism of action of Leuprolide. | Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in... |
How does Leuprolide work at a molecular level? | Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in... |
Describe the pharmacodynamics of Leuprolide. | Leuprolide is a gonadotropin-releasing hormone (GnRH) analogue that functions as a GnRH receptor superagonist.[A203132, A203222] After an initial spike in GnRH-mediated steroidal production, including testosterone and estradiol, prolonged use results in a significant drop in circulating steroid levels, in line with tho... |
What is the absorption profile of Leuprolide? | Leuprolide is typically administered as a single-dose long-acting formulation employing either microsphere or biodegradable solid depot technologies.[A203126] Regardless of the exact formulation and initial dose strength, the C<sub>max</sub> is typically achieved by 4-5 hours post-injection and displays large variabili... |
What is the half-life of Leuprolide? | Leuprolide has a terminal elimination half-life of approximately three hours.[L10310, L13781, L13784, L13787, L13790, L13814, L34415] |
What is the protein binding percentage of Leuprolide? | Leuprolide displays _in vitro_ binding to human plasma proteins between 43% and 49%.[L10310, L13781, L13784, L13787, L13790, L13814, L34415] |
How is Leuprolide eliminated from the body? | Following administration of 3.75 mg leuprolide depot suspension to three patients, less than 5% of the initial dose was recovered as unchanged or pentapeptide metabolite in the urine.[L10310, L13781, L13784, L13814] |
What are the toxic effects or overdose risks of Leuprolide? | Leuprolide is considered extremely safe, with low dose-related toxicity and comparatively mild adverse effects.[A203126] Prostate cancer patients treated with leuprolide at doses as high as 20 mg/day for two years showed no additional adverse effects compared to those receiving 1 mg/day.[L13814] |
What is Peginterferon alfa-2a? | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... |
Give me an overview of the drug Peginterferon alfa-2a. | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... |
What are the clinical indications for Peginterferon alfa-2a? | Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alf... |
When should a clinician prescribe Peginterferon alfa-2a? | Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alf... |
Explain the mechanism of action of Peginterferon alfa-2a. | Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involv... |
How does Peginterferon alfa-2a work at a molecular level? | Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involv... |
What is the absorption profile of Peginterferon alfa-2a? | Peginterferon alfa-2a reaches peak plasma concentration 72-96 hours after subcutaneous administration [FDA Label]. Trough concentrations at week 48 are approximately 2 fold higher than week 1. The peak to trough ratio at week 48 is 2. |
What is the half-life of Peginterferon alfa-2a? | The mean terminal half-life of peginterferon alfa-2a is 164 in a range of 84-353 hours [FDA Label]. |
What are the toxic effects or overdose risks of Peginterferon alfa-2a? | Peginterferon alfa-2a may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose [FDA Label]. Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have been observed in patients using Peginterf... |
What happens when Peginterferon alfa-2a is combined with Denosumab? | The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon alfa-2a. |
What happens when Peginterferon alfa-2a is combined with Etanercept? | The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2a. |
What happens when Peginterferon alfa-2a is combined with Interferon alfa-n1? | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-n1. |
Give me an overview of the drug Alteplase. | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between ... |
What are the clinical indications for Alteplase? | Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow ... |
When should a clinician prescribe Alteplase? | Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow ... |
Explain the mechanism of action of Alteplase. | Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the absence of fibrin, alteplase converts a limited amount of plasminogen. However, in the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at po... |
Describe the pharmacodynamics of Alteplase. | Alteplase binds to fibrin and plasminogen. Alteplase specificity for fibrin is achieved thanks to its high affinity for lysine residues. Also, it can bind plasminogen via loop structures called kringles, stabilized by three disulphide linkages similar to the ones in plasminogen. The specificity of alteplase for plasmin... |
What is the absorption profile of Alteplase? | Healthy volunteers with a baseline endogenous tissue plasminogen activator (t-PA) of 3.3 ng/ml had a 290-fold increase in baseline concentrations after receiving alteplase at an infusion rate of 0.25 mg/kg for 30 min; with an infusion rate of 0.5 mg/kg, a 550-fold increase was observed.[A252270] Acute myocardial infarc... |
What is the half-life of Alteplase? | Alteplase has an initial half-life of less than 5 minutes in patients with acute myocardial infarction (AMI). The dominant initial plasma half-life of the 3-hour and the accelerated regimens for AMI are similar.[L43125] |
What are the toxic effects or overdose risks of Alteplase? | Toxicity information regarding alteplase is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as risk of bleeding and thromboembolic events.[L43125] Symptomatic and supportive measures are recommended. The carcinogenic potential of alteplase or its effect o... |
Give me an overview of the drug Sermorelin. | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues |
What are the clinical indications for Sermorelin? | For the treatment of dwarfism, prevention of HIV-induced weight loss |
When should a clinician prescribe Sermorelin? | For the treatment of dwarfism, prevention of HIV-induced weight loss |
Explain the mechanism of action of Sermorelin. | Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion. |
How does Sermorelin work at a molecular level? | Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion. |
Describe the pharmacodynamics of Sermorelin. | Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans... |
Give me an overview of the drug Interferon alfa-n1. | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. |
What are the clinical indications for Interferon alfa-n1? | For the treatment of venereal or genital warts caused by the Human Papiloma Virus. |
When should a clinician prescribe Interferon alfa-n1? | For the treatment of venereal or genital warts caused by the Human Papiloma Virus. |
DrugBank Clean β Instruction-Tuning Dataset for Pharmacology AI
A high-quality, instruction-tuned dataset of 45,805 question-answer pairs derived from DrugBank, designed for fine-tuning LLMs on pharmacological knowledge. Built to power the next generation of clinical AI systems with deep pharmacology expertise.
π― Why This Dataset
Most general-purpose LLMs lack deep pharmacological knowledge β they hallucinate dosages, miss drug interactions, and oversimplify clinical mechanisms. This dataset addresses that gap by providing clean, structured, instruction-tuned data specifically for fine-tuning models on:
- π Drug overviews and clinical descriptions
- π©Ί Indications and clinical use cases
- 𧬠Mechanism of action (molecular level)
- π Pharmacodynamics & pharmacokinetics
- β οΈ Drug-drug interactions
- π¬ Absorption, half-life, protein binding
- π¨ Toxicity profiles and overdose risks
π Dataset Statistics
| Metric | Value |
|---|---|
| Rows | 45,805 |
| Format | JSONL (instruction-output pairs) |
| Fields | instruction, output |
| Source | DrugBank database (cleaned & restructured) |
| License | MIT |
| Language | English |
𧬠Question Categories Covered
The dataset covers 10+ pharmacology dimensions per drug:
- β Drug overviews ("Give me an overview of [drug]")
- β Clinical indications ("What are the clinical indications for [drug]?")
- β Prescriber guidance ("When should a clinician prescribe [drug]?")
- β Mechanism of action (high-level + molecular)
- β Pharmacodynamics
- β Absorption profiles
- β Half-life data
- β Protein binding percentages
- β Elimination pathways
- β Toxicity & overdose risks
- β Drug-drug interaction warnings
π Use Cases
This dataset is ideal for:
- Fine-tuning LLMs for clinical decision support (LoRA, QLoRA on Llama, Mistral, BioMistral, Phi)
- Training pharmacology chatbots (patient-facing or clinician-facing)
- Retrieval-Augmented Generation (RAG) systems for healthcare
- Drug information question-answering systems
- Educational AI tutors for pharmacy students
- Research benchmarks for medical LLM evaluation
π₯ Quick Start
Load with datasets library:
from datasets import load_dataset
dataset = load_dataset("Oduwo/drugbank-clean")
print(dataset)
print(dataset["train"][0])
Sample row format:
{
"instruction": "Give me an overview of the drug Lepirudin.",
"output": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor..."
}
Fine-tune with QLoRA (example):
from transformers import AutoTokenizer, AutoModelForCausalLM
from peft import LoraConfig, get_peft_model
from datasets import load_dataset
dataset = load_dataset("Oduwo/drugbank-clean", split="train")
model = AutoModelForCausalLM.from_pretrained("BioMistral/BioMistral-7B")
# ... continue with your fine-tuning pipeline
π οΈ Data Pipeline
The dataset was built using a custom streaming XML parser for the DrugBank database, with the following processing steps:
- Extraction β DrugBank XML parsed via streaming for memory efficiency
- Restructuring β Raw drug records transformed into instruction-output pairs
- Deduplication β Removed exact and near-duplicate entries
- Format standardization β Converted to clean JSONL for LLM training
- Quality validation β Manual review of sample entries
β οΈ Limitations
- Source: Derived from DrugBank β inherits any limitations of that source
- Language: English only
- Currency: Reflects DrugBank version at time of curation
- Use case: Designed for AI training; not a substitute for clinical references like UpToDate, Lexicomp, or Micromedex
- Clinical disclaimer: Models trained on this data are for educational and research purposes only. Always verify with authoritative clinical sources before applying in patient care.
π Citation
If you use this dataset in your research or product, please cite:
@dataset{oduwo2026drugbank_clean,
author = {Emmanuel Bain Oduwo},
title = {DrugBank Clean: Instruction-Tuning Dataset for Pharmacology AI},
year = {2026},
publisher = {Hugging Face},
url = {https://huggingface.co/datasets/Oduwo/drugbank-clean}
}
π Related Projects
This dataset powers several of my healthcare AI projects:
- Kemirix β Self-hosted pharmacology LLM (BioMistral 7B + QLoRA)
- DrugD Clinical AI β Drug information & interaction platform
- PharmaCliniq Pro β Clinical decision support tool
- Africa Pharmacovigilance ADR Dataset β Open-source African drug safety data
π¨βπ» Author
Emmanuel Bain Oduwo
Healthcare AI/ML Engineer | B.Pharm Student | Founder, TechFryz
Building production-grade clinical AI tools that bridge pharmacology and machine learning, with a focus on African healthcare contexts.
- π§ Email: bainemmanuel86@gmail.com
- π± WhatsApp: +254 707 862 452
π€ Contributing
Found an issue? Have suggestions? Open a discussion on the Community tab. Contributions to expand coverage (e.g., African pharmacology, traditional medicine integrations) are especially welcome.
π License
MIT License β free for research, educational, and commercial use with attribution.
- Downloads last month
- 146